Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue.

Colin Howden, D. W. Burget, C. Silletti, A. Van Eeden, K. B. Tomkins, R. H. Hunt

Research output: Contribution to journalArticle

Abstract

The gastric antisecretory effects of three different doses of enisoprost, a new synthetic PGE1 analogue, were compared with placebo and misoprostol in 20 healthy male volunteers. Enisoprost 100, 200 and 400 micrograms all significantly (P less than 0.0001; ANOVA) suppressed histamine-stimulated acid and pepsin output when compared with placebo or misoprostol 200 micrograms. Misoprostol produced a significant decrease of stimulated acid output when compared with placebo (P = 0.0012). The concentration of pepsin in gastric juice was significantly (P less than 0.0001) decreased by enisoprost at the commencement of histamine stimulation. This effect was short-lived, and was maximal with enisoprost 400 micrograms. There was a significant dose-response relationship for enisoprost for inhibition of stimulated acid output (P = 0.0065). Enisoprost was well tolerated, and no consistent drug-related adverse effects were detected. The profile of antisecretory effect of enisoprost, producing marked suppression of both acid and pepsin secretion independently, is unusual. This combination of activity along with any mucosal protective properties might be particularly effective in the treatment of peptic ulcer disease.

Original languageEnglish (US)
Pages (from-to)305-313
Number of pages9
JournalAlimentary pharmacology & therapeutics
Volume1
Issue number4
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Alprostadil
Pepsin A
Gastric Acid
Misoprostol
Acids
Placebos
Histamine
Gastric Juice
enisoprost
Peptic Ulcer
Stomach
Analysis of Variance
Healthy Volunteers
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

Howden, C., Burget, D. W., Silletti, C., Van Eeden, A., Tomkins, K. B., & Hunt, R. H. (1987). Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue. Alimentary pharmacology & therapeutics, 1(4), 305-313.

Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue. / Howden, Colin; Burget, D. W.; Silletti, C.; Van Eeden, A.; Tomkins, K. B.; Hunt, R. H.

In: Alimentary pharmacology & therapeutics, Vol. 1, No. 4, 01.01.1987, p. 305-313.

Research output: Contribution to journalArticle

Howden, C, Burget, DW, Silletti, C, Van Eeden, A, Tomkins, KB & Hunt, RH 1987, 'Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue.', Alimentary pharmacology & therapeutics, vol. 1, no. 4, pp. 305-313.
Howden, Colin ; Burget, D. W. ; Silletti, C. ; Van Eeden, A. ; Tomkins, K. B. ; Hunt, R. H. / Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue. In: Alimentary pharmacology & therapeutics. 1987 ; Vol. 1, No. 4. pp. 305-313.
@article{5c7d7561a9214ca1ac609807cea38b23,
title = "Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue.",
abstract = "The gastric antisecretory effects of three different doses of enisoprost, a new synthetic PGE1 analogue, were compared with placebo and misoprostol in 20 healthy male volunteers. Enisoprost 100, 200 and 400 micrograms all significantly (P less than 0.0001; ANOVA) suppressed histamine-stimulated acid and pepsin output when compared with placebo or misoprostol 200 micrograms. Misoprostol produced a significant decrease of stimulated acid output when compared with placebo (P = 0.0012). The concentration of pepsin in gastric juice was significantly (P less than 0.0001) decreased by enisoprost at the commencement of histamine stimulation. This effect was short-lived, and was maximal with enisoprost 400 micrograms. There was a significant dose-response relationship for enisoprost for inhibition of stimulated acid output (P = 0.0065). Enisoprost was well tolerated, and no consistent drug-related adverse effects were detected. The profile of antisecretory effect of enisoprost, producing marked suppression of both acid and pepsin secretion independently, is unusual. This combination of activity along with any mucosal protective properties might be particularly effective in the treatment of peptic ulcer disease.",
author = "Colin Howden and Burget, {D. W.} and C. Silletti and {Van Eeden}, A. and Tomkins, {K. B.} and Hunt, {R. H.}",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "305--313",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue.

AU - Howden, Colin

AU - Burget, D. W.

AU - Silletti, C.

AU - Van Eeden, A.

AU - Tomkins, K. B.

AU - Hunt, R. H.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - The gastric antisecretory effects of three different doses of enisoprost, a new synthetic PGE1 analogue, were compared with placebo and misoprostol in 20 healthy male volunteers. Enisoprost 100, 200 and 400 micrograms all significantly (P less than 0.0001; ANOVA) suppressed histamine-stimulated acid and pepsin output when compared with placebo or misoprostol 200 micrograms. Misoprostol produced a significant decrease of stimulated acid output when compared with placebo (P = 0.0012). The concentration of pepsin in gastric juice was significantly (P less than 0.0001) decreased by enisoprost at the commencement of histamine stimulation. This effect was short-lived, and was maximal with enisoprost 400 micrograms. There was a significant dose-response relationship for enisoprost for inhibition of stimulated acid output (P = 0.0065). Enisoprost was well tolerated, and no consistent drug-related adverse effects were detected. The profile of antisecretory effect of enisoprost, producing marked suppression of both acid and pepsin secretion independently, is unusual. This combination of activity along with any mucosal protective properties might be particularly effective in the treatment of peptic ulcer disease.

AB - The gastric antisecretory effects of three different doses of enisoprost, a new synthetic PGE1 analogue, were compared with placebo and misoprostol in 20 healthy male volunteers. Enisoprost 100, 200 and 400 micrograms all significantly (P less than 0.0001; ANOVA) suppressed histamine-stimulated acid and pepsin output when compared with placebo or misoprostol 200 micrograms. Misoprostol produced a significant decrease of stimulated acid output when compared with placebo (P = 0.0012). The concentration of pepsin in gastric juice was significantly (P less than 0.0001) decreased by enisoprost at the commencement of histamine stimulation. This effect was short-lived, and was maximal with enisoprost 400 micrograms. There was a significant dose-response relationship for enisoprost for inhibition of stimulated acid output (P = 0.0065). Enisoprost was well tolerated, and no consistent drug-related adverse effects were detected. The profile of antisecretory effect of enisoprost, producing marked suppression of both acid and pepsin secretion independently, is unusual. This combination of activity along with any mucosal protective properties might be particularly effective in the treatment of peptic ulcer disease.

UR - http://www.scopus.com/inward/record.url?scp=0023386713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023386713&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 305

EP - 313

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -